Worldquant Millennium Advisors LLC Has $46.27 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Worldquant Millennium Advisors LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1,537.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 235,444 shares of the medical research company's stock after buying an additional 221,064 shares during the quarter. Worldquant Millennium Advisors LLC owned approximately 0.13% of IQVIA worth $46,267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Howard Capital Management Inc. grew its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the period. Harbor Investment Advisory LLC grew its holdings in IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the period. Magnolia Capital Advisors LLC grew its holdings in IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after purchasing an additional 74 shares during the period. New York Life Investment Management LLC grew its holdings in IQVIA by 0.4% during the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock valued at $4,537,000 after purchasing an additional 81 shares during the period. Finally, Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

IQVIA stock traded down $1.08 during trading hours on Friday, reaching $136.96. 2,248,506 shares of the stock were exchanged, compared to its average volume of 1,560,203. The company has a market cap of $23.69 billion, a P/E ratio of 18.26, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The stock has a 50 day moving average of $155.33 and a two-hundred day moving average of $183.37.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.54 earnings per share. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IQV shares. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Barclays cut their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday. Finally, Wall Street Zen downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.14.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.